Initial data presented at the American College of Cardiology meeting in late March suggest similar LDL lowering for the most advanced PCSK9 inhibitors, evolocumab from Amgen Inc. (NASDAQ:AMGN) and alirocumab from partners Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY). However, the most relevant data sets for comparison will come from studies in patients with heterozygous familial hypercholesterolemia (heFH) and statin-intolerant patients. Each of the Phase III programs